Investigational drug · Phase 3
RAY1225
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, T2DM, T2DM (Type 2 Diabetes Mellitus).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
12
Any phase or sponsor naming "RAY1225"
First trial start
2024
Feb 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RAY1225", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- T2DM
- T2DM (Type 2 Diabetes Mellitus)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "RAY1225" as an intervention, largest first.
- Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightPivotal-lookingRecruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06893016 · 640 participants (planned) · Start Jun 15, 2025 · Primary completion Jun 15, 2026
Drug: RAY1225; Placebo · For: Obesity
Sites: Beijing, China
- A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesPivotal-lookingNot yet recruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07139548 · 600 participants (planned) · Start Aug 31, 2025 · Primary completion Dec 1, 2026
Drug: RAY1225; Semaglutide · For: T2DM
Sites: Beijing, China
- A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AlonePivotal-lookingNot yet recruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07139535 · 350 participants (planned) · Start Aug 31, 2025 · Primary completion Dec 1, 2026
Drug: RAY1225; placebo · For: T2DM
Sites: Beijingcun, China
- A Study of RAY1225 in Participants With ObesityPivotal-lookingRecruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06254261 · 270 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 20, 2025
Drug: RAY1225; Placebo · For: Obesity
Sites: Beijingcun, China
- A Study of RAY1225 in Participants With Type 2 DiabetesPivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06254274 · 210 participants · Start Feb 26, 2024 · Primary completion Jul 20, 2025
Drug: RAY1225; Placebo · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Beijingcun, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07827027 · 68 participants (planned) · Start Sep 21, 2026 · Primary completion Nov 5, 2026
Drug: RAY1225 · For: Basic Science
Guangdong Raynovent Biotech Co., LtdIndustry
NCT05835752 · 68 participants · Start May 18, 2023 · Primary completion Mar 1, 2024
Drug: RAY1225; Placebo and 4 more · For: Obese; Healthy
Sites: Guangzhou, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06577428 · 48 participants · Start Jul 30, 2024 · Primary completion Sep 29, 2024
Drug: RAY1225 · For: Healthy
Sites: Guanzhou, China
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and DigoxinActive, not recruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07362030 · 32 participants · Start Apr 14, 2025 · Primary completion Dec 27, 2025
Drug: RAY1225; atorvastatin calcium tablet and 3 more · For: Obesity
Sites: Dongguan, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06613763 · 32 participants · Start Sep 11, 2024 · Primary completion Jan 10, 2025
Drug: RAY1225 · For: Kidney Impairment
Sites: Xiamen, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.